as 12-17-2024 4:00pm EST
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Founded: | 2019 | Country: | United States |
Employees: | N/A | City: | DALLAS |
Market Cap: | 403.7M | IPO Year: | 2020 |
Target Price: | $6.63 | AVG Volume (30 days): | 5.4M |
Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.10 | EPS Growth: | N/A |
52 Week Low/High: | $1.19 - $4.32 | Next Earning Date: | 11-13-2024 |
Revenue: | $9,915,000 | Revenue Growth: | -30.90% |
Revenue Growth (this year): | -45.49% | Revenue Growth (next year): | -39.74% |
TSHA Breaking Stock News: Dive into TSHA Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Simply Wall St.
a month ago
Thomson Reuters StreetEvents
a month ago
GuruFocus.com
a month ago
Zacks
a month ago
GlobeNewswire
a month ago
Simply Wall St.
a month ago
GlobeNewswire
a month ago
The information presented on this page, "TSHA Taysha Gene Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.